Chunqiao Tian

Chunqiao Tian

Auto-generated profile, based on publicly available information

Chunqiao Tian

Gynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Gynecologic Oncology
Verified
Journal Article
Closed access
CRChristine Rojas
Christine Rojas
CTChunqiao Tian
Chunqiao Tian
MPMatthew A. Powell
Matthew A. Powell
JCJohn K. Chan
John K. Chan
NBNicholas W. Bateman
Nicholas W. Bateman
KDKathleen M Darcy
Kathleen M Darcy


1 April 2020 in Gynecologic Oncology
Verified
Journal Article
Closed access
NGNicole B. Gaulin
Nicole B. Gaulin
JLJamie L. Lesnock
Jamie L. Lesnock
CTChunqiao Tian
Chunqiao Tian
KOKathryn Osei-Bonsu
Kathryn Osei-Bonsu
AJAllison Jacobs
Allison Jacobs
KDKathleen M Darcy
Kathleen M Darcy

23 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
YCYovanni Casablanca
Yovanni Casablanca
GWGuisong Wang
Guisong Wang
HLHeather A. Lankes
Heather A. Lankes
CTChunqiao Tian
Chunqiao Tian
NBNicholas W. Bateman
Nicholas W. Bateman
GMGeorge Larry Maxwell
George Larry Maxwell
Objectives: A risk assessment model for metastasis in endometrioid endometrial cancer (EEC) was developed using molecular and clinical features, and prognostic association was examined. Methods: Patients had stage I, IIIC, or IV EEC with tumor-derived RNA-sequencing or microarray-based data. Metastasis-associated transcripts and platform-centric diagnostic algorithms were selected and evaluated using regression modeling and receiver operating characteristic curves. Results: Seven metastasis-associated transcripts were selected from analysis in the training cohorts using 10-fold cross validation and incorporated into an MS7 classifier using platform-specific coefficients. The predictive accuracy of the MS7 classifier in Training-1 was superior to that of other clinical and molecular features, with an area under the curve (95% confidence interval) of 0.89 (0.80–0.98) for MS7 compared with 0.69 (0.59–0.80) and 0.71 (0.58–0.83) for the top evaluated clinical and molecular features, respectively. The performance of MS7 was independently validated in 245 patients using RNA sequencing and in 81 patients using microarray-based data. MS7 + MI (myometrial invasion) was preferrable to individual features and exhibited 100% sensitivity and negative predictive value. The MS7 classifier was associated with lower progression-free and overall survival (p ≤ 0.003). Conclusion: A risk assessment classifier for metastasis and prognosis in EEC patients with primary tumor derived MS7 + MI is available for further development and optimization as a companion clinical support tool.

1 December 2016 in Gynecologic Oncology Research and Practice
Verified
Journal Article
Open access
PDF file
BDBrittany A. Davidson
Brittany A. Davidson
JFJonathan Foote
Jonathan Foote
SBStacey L. Brower
Stacey L. Brower
CTChunqiao Tian
Chunqiao Tian
LHLaura J. Havrilesky
Laura J. Havrilesky
ASAngeles Alvarez Secord
Angeles Alvarez Secord
Chemotherapy plays a role in the treatment of endometrioid endometrial cancer (EEC); however, tumor grade may affect response. Our objective was to evaluate associations between tumor grade and in vitro chemoresponse. We conducted an analysis of primary tumor samples from women with EEC undergoing in vitro chemoresponse testing. Results were classified as sensitive (S), intermediate (I), or resistant (R) to each drug tested. Correlations between tumor grade and response were examined. Data was collected from 159 patients: 28 with grade 1 (18%), 52 with grade 2 (32%), and 79 (50%) with grade 3 tumors. Median age of patients was 62 (range 31–92). Most patients were Caucasian (83%) with advanced disease (Stage III: 50.9%; Stage IV: 13.2%). Overall chemoresponse was similar across all grades. Fifty percent, 56 and 51% for grade 1, 2, and 3 tumors, respectively, demonstrated S results to at least 1 agent. There was no association between grade and in vitro response to chemotherapy agents (p > 0.05) except a marginal association between grade and doxorubicin response (p = 0.08). Grade 1 and 2 cancers were more likely to demonstrate R results for doxorubicin compared to grade 3 cancers (G1: 19% vs G2: 25% vs G3: 8%; p = 0.08). In a subset tested for all 7 agents, only one patient tumor was pan-R and 4 were pan-S. Based on our data, grades 1–3 EEC have similar in vitro chemoresponse. These findings suggest that chemotherapy may be useful in advanced low grade EECs, but further clinical correlation is needed.

6 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CSCollin A. Sitler
Collin A. Sitler
CTChunqiao Tian
Chunqiao Tian
CHChad A. Hamilton
Chad A. Hamilton
MRMichael Richardson
Michael Richardson
JCJohn K. Chan
John K. Chan
KDKathleen M Darcy
Kathleen M Darcy
Purpose: To investigate IMT use and survival in real-world stage IVB cervical cancer patients outside randomized clinical trials. Methods: Patients diagnosed with stage IVB cervical cancer during 2013–2019 in the National Cancer Database and treated with chemotherapy (CT) ± external beam radiation (EBRT) ± intracavitary brachytherapy (ICBT) ± IMT were studied. The adjusted hazard ratio (AHR) and 95% confidence interval (CI) for risk of death were estimated in patients treated with vs. without IMT after applying propensity score analysis to balance the clinical covariates. Results: There were 3164 evaluable patients, including 969 (31%) who were treated with IMT. The use of IMT increased from 11% in 2013 to 46% in 2019. Age, insurance, facility type, sites of distant metastasis, and type of first-line treatment were independently associated with using IMT. In propensity-score-balanced patients, the median survival was 18.6 vs. 13.1 months for with vs. without IMT (p < 0.001). The AHR was 0.72 (95% CI = 0.64–0.80) for adding IMT overall, 0.72 for IMT + CT, 0.66 for IMT + CT + EBRT, and 0.69 for IMT + CT + EBRT + ICBT. IMT-associated survival improvements were suggested in all subgroups by age, race/ethnicity, comorbidity score, facility type, tumor grade, tumor size, and site of metastasis. Conclusions: IMT was associated with a consistent survival benefit in real-world patients with stage IVB cervical cancer.